Key result
Extended anticoagulation with apixaban 2.5 mg or 5 mg twice daily significantly reduced the risk of hospitalization compared with placebo (HR 0.65, P=0.030 and HR 0.54, P=0.004).
Why the study?
Does apixaban reduce all-cause hospitalizations in patients with VTE who have completed 6-12 months of anticoagulation therapy?
RCT (n=2,477)
Double-blind
Does apixaban reduce all-cause hospitalizations in patients with VTE who have completed 6-12 months of anticoagulation therapy?
Hazard Ratio: 0.65 (95% CI 0.44–0.96)
Absolute Event Rate: 4.8% vs 7.5%
p-value: p=0.030
Extended anticoagulation with apixaban (2.5 mg or 5 mg twice daily) significantly reduces the risk of all-cause hospitalization in patients with VTE who have completed initial anticoagulation therapy.
No takes yet. Share an insight, caveat, or question.
Extended apixaban reduces hospitalizations after VTE; extends RCT evidence beyond recurrent events to overall clinical burden.
Liu et al. (2013) conducted an RCT in Venous thromboembolism (n=2,477). Apixaban vs. Placebo was evaluated on All-cause hospitalizations (HR 0.65, 95% CI 0.44-0.96, p=0.030). Extended anticoagulation with apixaban 2.5 mg or 5 mg twice daily significantly reduced the risk of hospitalization compared with placebo (HR 0.65, P=0.030 and HR 0.54, P=0.004).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: